JANSSEN Pharmaceuticals has confirmed the Pharmaceutical Benefits Listing of Stelara (ustekinumab) for the treatment of adults with severe Crohn's disease.
It is the first and only interleukin (IL)-12/23 inhibitor to be PBS-listed, with the addition to the schedule effective 01 Sep 2017.
Stelara, which is also registered for use for the treatment of psoriasis and psoriatic arthritis, targets IL-12 and IL-23 through a one-time weight-based intravenous induction dose, followed by subcutaneous maintenance therapy injections every 8 weeks.
The above article was sent to subscribers in Pharmacy Daily's issue from 30 Aug 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 30 Aug 17
